Prosecution Insights
Last updated: August 06, 2026

Caliway Biopharmaceuticals Co. Ltd.

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (33%)
2
Medium (67%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (67%)
Multi-statute (no §101)1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MELLER, MICHAEL V 1 47.2% +28.1%
GALSTER, SAMUEL LEONARD 1 52.3% +41.7%
YU, HONG 1 31.1% +5.5%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
15754363 A PHARMACEUTICAL COMPOSITION FOR REDUCING LOCAL FAT AND USES THEREOF YU, HONG

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18466003 METHOD FOR TREATING AND/OR PREVENTING EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY MELLER, MICHAEL V
18317564 COMPOSITIONS AND METHODS FOR ALLEVIATING CONDITIONS CAUSED BY ABNORMAL SUBCUTANEOUS DEPOSIT OF ADIPOSE TISSUE OR FAT GALSTER, SAMUEL LEONARD

Top Art Units

Art UnitApps
1655 1
1693 1
1614 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18466003 METHOD FOR TREATING AND/OR PREVENTING EDEMATOUS FIBROSCLEROTIC PANNICULOPATHY MELLER, MICHAEL V 1655 §103 Final Rejection Pending Sep 13, 2023
18317564 COMPOSITIONS AND METHODS FOR ALLEVIATING CONDITIONS CAUSED BY ABNORMAL SUBCUTANEOUS DEPOSIT OF ADIPOSE TISSUE OR FAT GALSTER, SAMUEL LEONARD 1693 §103Other Final Rejection Pending May 15, 2023
15754363 A PHARMACEUTICAL COMPOSITION FOR REDUCING LOCAL FAT AND USES THEREOF YU, HONG 1614 §102§103§112 Non-Final OA Pending Feb 22, 2018

Managing Caliway Biopharmaceuticals Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month